Brock Summers
Psychiatry · Glendale, CANPI 1457492555
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,058 of the $8,932 with a category attached, or 79.0%. It is spread thinly across 20 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $3,324 and has fallen 98.2% since, to $61 in 2024. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $28.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Merck$2K
- Otsuka America Pharmaceutical, Inc.$761
- Supernus Pharmaceuticals, Inc.$705
- Sunovion Pharmaceuticals Inc.$686
- Lundbeck LLC$656
- plus $2K from 14 others
Across 202 payments — averaging $10,202 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.3M
- Supernus Pharmaceuticals, Inc.$253K
- Genentech, Inc.$145K
- Sunovion Pharmaceuticals Inc.$87K
- Merck$77K
- Purdue Pharma L.p.$48K
- plus $159K from 7 others
What the payments were for
- Speaking & faculty fees$5006%
- Travel & lodging$1,37415%
- Food & beverage$7,05879%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 87 | $1,871 |
| Merck | 14 | $1,814 |
| Otsuka America Pharmaceutical, Inc. | 39 | $761 |
| Supernus Pharmaceuticals, Inc. | 4 | $705 |
| Sunovion Pharmaceuticals Inc. | 31 | $686 |
| Lundbeck LLC | 27 | $656 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $620 |
| AbbVie(2 entities) | 28 | $531 |
| Alkermes, Inc. | 18 | $442 |
| Johnson & Johnson | 11 | $259 |
| Vanda Pharmaceuticals Inc. | 10 | $247 |
| Axsome Therapeutics, Inc. | 3 | $94 |
| Avanir Pharmaceuticals, Inc. | 2 | $50 |
| Adlon Therapeutics L.p. | 2 | $40 |
| Eisai Inc. | 2 | $38 |
| Livanova USA, Inc. | 1 | $36 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Noven Therapeutics, LLC | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Neuronetics, Inc. | 1 | $4 |
How this compares
$8,932 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bupropion XlBupropion Hcl | 11 | $156 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Glendale
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.